Browsing Tag
American Diabetes Association
8 posts
Insulet Omnipod 6 data puts PODD back in focus as automated insulin delivery moves toward type 2 diabetes
Read how Insulet Omnipod 6 data could reshape automated insulin delivery, type 2 diabetes care and PODD stock sentiment. Find out what changes next in 2026.
Pfizer (PFE) tests investor patience as berobenatide moves toward Phase 3 obesity trials
Find out how Pfizer’s berobenatide data could reshape its obesity drug strategy, GLP-1 competition and investor sentiment today!
DexCom (DXCM) gains strategic evidence edge as CONNECT study targets broader diabetes market
Find out how DexCom’s CONNECT study could expand CGM use in non-insulin Type 2 diabetes and reshape DXCM’s growth outlook.
Corcept Therapeutics (CORT) CATALYST data puts Korlym at centre of difficult-to-control diabetes strategy
Find out how Corcept Therapeutics’ ADA data could reshape cortisol screening in hard-to-control diabetes and GLP-1 care.
Eli Lilly’s oral GLP-1 Foundayo gains new women’s health angle with menopause weight-loss data
Lilly’s oral GLP-1 now targets menopause-linked weight gain. Read why Foundayo could sharpen the next obesity drug battleground.
Novo Nordisk eyes FDA approval for high-dose 7.2mg Wegovy after STEP UP trial shows 21% weight loss
Novo Nordisk seeks U.S. approval for 7.2mg Wegovy after 21% average weight loss in trials. Can it outpace Eli Lilly’s Zepbound in the obesity drug race?
EmpathyTech launches culturally intelligent AI to close chronic care gap for Black Americans
EmpathyTech launches AI health platform for Black Americans, blending wearables, nudges, and storytelling to close chronic care gaps.
Lilly’s oral GLP-1 pill cuts blood sugar and weight without injections—Here’s what the breakthrough data shows
Lilly’s oral GLP-1 drug orforglipron showed strong A1C and weight loss results in Phase 3—find out how it could change diabetes care worldwide.